Leerink Partners Downgrades Innate Pharma to Market Perform, Lowers Price Target to $2
Benzinga Newsdesk 1 year ago
NewsDowngradesPrice TargetAnalyst Ratings
Leerink Partners analyst Daina Graybosch downgrades Innate Pharma (NASDAQ:IPHA) from Outperform to Market Perform and lowers the price target from $10 to $2.
Leerink Partners analyst Daina Graybosch downgrades Innate Pharma (NASDAQ:IPHA) from Outperform to Market Perform and lowers the price target from $10 to $2.